TWICE-YEARLY DEPEMOKIMAB REDUCES EXACERBATIONS AND IMPROVES QUALITY OF LIFE IN PATIENTS WITH UNCONTROLLED ASTHMA SYMPTOMS AT BASELINE: SUBGROUP ANALYSES OF THE PHASE III SWIFT-1/2 STUDIES